Leerink Partners Incrementally More Positive on Jazz Pharma (JAZZ) Following Meetings with Management

Leerink Partners analyst Jason Gerberry reiterated an Outperform rating and $201 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) saying they are incrementally more positive following meetings with management.

Gerberry commented, "We recently hosted JAZZ mgmt. meetings with CFO Matt Young. Key takeaways from our meetings included: (1) Xyrem line extension pipeline focused on retaining value for the long haul; (2) Xyrem patent litigation remains fragmented and appears likely to end in a settlement; (3) US Defitelio market is being primed for quick uptake; & (4) M&A remains very high on mgmt's radar. Detailed notes are on pp. 2-3. We remain OP with a price target of $201."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $179.42 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Uber Inc. (UBER) PT Raised to $96 at Tigress Financial Partners
• London Stock Exchange Group Plc. (LSEG:LN) (LNSTY) PT Raised to GBP88 at HSBC